Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering
Acquisition follows increased investment in Envision from GHO Capital and its partners
London, UK, November 12, 2020
- Two Labs brings market-leading commercialization, strategic consulting, market access, and market intelligence solutions that span the full product life cycle
- Move builds on Envision’s established leadership position as the preferred tech-enabled scientific communications company for medical affairs, while deepening its presence in the critical US domestic market, and with small and midsize biopharma clients
- Group to deliver customized “launch excellence” offering, becoming a global go-to strategic partner for pharma in medical affairs, healthcare communications, and consulting services –charting the path from clinical to commercial for a new product, and guiding clients on the optimum journey
Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of Two Labs, an industry-leading provider of integrated and customized commercial solutions to the pharmaceutical and biotechnology sector.
The combined company will bring together complementary clients, services, and technologies, extending Envision’s scientific footprint to new clients in the “product pre-launch setting” – while opening up new business avenues and geographies for Two Lab’s best-in-class launch planning services.
Two Labs, founded in 2003 and headquartered in Powell, Ohio, has offices and operations across the US and UK, and is an established strategic consulting and commercialization provider to the biopharma industry. Two Labs helps pharmaceutical companies develop and execute customized launch strategies for products. It has a proven track record of successful launches across all major therapeutic areas with unmatched client satisfaction.
Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion. Since being founded in 2001, Envision has delivered strong year-on-year organic growth and established leadership in medical affairs strategy, medical communications, and enterprise-wide iEnvision® technology. A number of strategic acquisitions in medical strategy, Health Economics and Market Access (HEMA), and behavioral science-led communications have played an important role in its expansion.
David Thompson, CEO, Envision, said, “This exciting combination of Envision and Two Labs creates a compelling and unrivaled proposition in launch excellence partnership globally and in the US. We look forward to sharing our joint expertise and leveraging our complementary services across medical affairs and product launch planning to support our clients in their goal of bringing new medicines to market effectively and compliantly, to improve patient outcomes.”
Howard Miller, CEO, Two Labs, added, “We are delighted to be joining the Envision family and taking Two Labs to the next logical step in its successful journey to date. With Envision’s global footprint and Two Labs’ market-leading US footprint, we have a unique opportunity to enrich our client partnerships with more connected services across the launch continuum. The cultural fit between our organizations is compelling, and we look forward to a new chapter for Two Labs in partnering with David and the Envision team.”
The Partners at GHO commented, “We are glad to welcome Howard and the Two Labs team to the Envision Group. They have built a market-leading strategic consulting and commercialization business that in combination with Envision’s position as the ‘go-to’ tech-enabled scientific communications company will deliver major value to global pharma and biotech through a combined, unique launch excellence offering that accelerates and improves their route to market.”
Excellere Partners, a US-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies, will exit its investment in Two Labs following a successful 4-year partnership.